- Home
- HFBL vs RNXT Comparison
HFBL vs RNXT Comparison
Compare HFBL & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- RNXT
- Stock Information
- Founded
- HFBL 1924
- RNXT 2012
- Country
- HFBL United States
- RNXT United States
- Employees
- HFBL N/A
- RNXT N/A
- Industry
- HFBL Savings Institutions
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- HFBL Finance
- RNXT Health Care
- Exchange
- HFBL Nasdaq
- RNXT Nasdaq
- Market Cap
- HFBL 41.3M
- RNXT 44.6M
- IPO Year
- HFBL N/A
- RNXT 2021
- Fundamental
- Price
- HFBL $13.67
- RNXT $1.22
- Analyst Decision
- HFBL
- RNXT Strong Buy
- Analyst Count
- HFBL 0
- RNXT 2
- Target Price
- HFBL N/A
- RNXT $7.50
- AVG Volume (30 Days)
- HFBL 1.3K
- RNXT 646.9K
- Earning Date
- HFBL 10-28-2025
- RNXT 11-12-2025
- Dividend Yield
- HFBL 3.85%
- RNXT N/A
- EPS Growth
- HFBL 6.78
- RNXT N/A
- EPS
- HFBL 1.26
- RNXT N/A
- Revenue
- HFBL $20,802,000.00
- RNXT $662,000.00
- Revenue This Year
- HFBL N/A
- RNXT $2,988.37
- Revenue Next Year
- HFBL N/A
- RNXT $300.60
- P/E Ratio
- HFBL $10.71
- RNXT N/A
- Revenue Growth
- HFBL 1.50
- RNXT N/A
- 52 Week Low
- HFBL $11.75
- RNXT $0.75
- 52 Week High
- HFBL $14.25
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- HFBL 56.53
- RNXT 55.80
- Support Level
- HFBL $13.34
- RNXT $1.19
- Resistance Level
- HFBL $13.44
- RNXT $1.45
- Average True Range (ATR)
- HFBL 0.08
- RNXT 0.12
- MACD
- HFBL 0.02
- RNXT 0.02
- Stochastic Oscillator
- HFBL 97.06
- RNXT 54.90
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.